It’s no secret that the life sciences industry has had some challenging moments with lawmakers in recent years. And despite efforts by the White House, Congress, FDA, and other regulatory agencies, in most cases the law continues to lag behind the industry’s pace of innovation. So, how will the Trump Administration address the industry’s challenges?
Senator Norm Coleman, Of Counsel at Hogan Lovells, was joined by the following panelists at Biotech Showcase to discuss:
- Jane Axelrad, Principal, Axelrad Solutions LLC, Former Associate Director for Policy, Center for Drug Evaluation and Research, FDA
- Julie Gerberding, Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health, Merck & Co., Inc.
- Greg Simon, Executive Director, White House Cancer Moonshot Task Force
[via EDB Group]